Joseph B. McGee Turner

Joseph B. McGee Turner

Auto-generated profile, based on publicly available information

Joseph B. McGee Turner

Department of Chemistry, Virginia Commonwealth University, Richmond, Virginia

Research Focus & Metrics

Academic Career Length

26Years (2001-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
9 October 2017 in ACS Applied Materials & Interfaces
Verified
Journal Article
Closed access
YAYomna H. Abdelmoaty
Yomna H. Abdelmoaty
TTTsemre-Dingel Tessema
Tsemre-Dingel Tessema
NNNazgol Norouzi
Nazgol Norouzi
OEOussama El-Kadri
Oussama El-Kadri
JTJoseph B. McGee Turner
Joseph B. McGee Turner
HEHani M. El-Kaderi
Hani M. El-Kaderi

1 October 2018 in Journal of Analytical Toxicology
Verified
Journal Article
Open access
PDF file
MPMichelle Peace
Michelle Peace
HMHaley A Mulder
Haley A Mulder
TBTyson R Baird
Tyson R Baird
KBKaren E Butler
Karen E Butler
AFAlaina K Friedrich
Alaina K Friedrich
JPJustin L Poklis
Justin L Poklis
Electronic cigarettes (e-cigs) deliver nicotine in an aerosol to the user that simulates the smoke of traditional cigarettes purportedly without the pathology of inhaling tobacco smoke due to the absence of combustion. Advanced versions of e-cigs enable the user to potentially moderate the concentration of drug in the aerosol by selecting from a range of voltages on the power supply. A method was developed to trap the aerosol produced by a KangerTech AeroTank, 1.8 Ω preassembled atomizer in order to analyze the concentration of nicotine and to evaluate the constituents of the aerosol at various voltages on the power supply. A 12-mg/mL formulation of nicotine in 50:50 propylene glycol (PG):vegetable glycerin (VG) was used to produce aerosol at 3.9, 4.3 and 4.7 V. The aerosol was trapped in a simple glass assemblage and analyzed by a 3200 Q Trap HPLC–MS-MS. The dose of nicotine delivered in the aerosol at 3.9, 4.3 and 4.7 V was determined to be 88 ± 12 μg, 91 ± 15 μg and 125 ± 22 μg. The average recovery of nicotine in the trap across the voltages was 99.8%. The glass trap system was an effective device for collecting the aerosol for analysis and an increase in drug yield was observed with increasing voltage from the power supply on the e-cig. The glass trap system was also used in combination with a 100-μm solid-phase microextraction fiber to capture the aerosol and analyze it via DART–MS and GC–MS. Four commercial e-liquids labeled to contain nicotine were aerosolized at 4.3 V. The pharmacologically active ingredient, nicotine, as well as PG, VG and a number of flavoring agents found in these formulations were identified.

15 July 2019 in Scientific Reports
Verified
Journal Article
Open access
PDF file
HMHaley A. Mulder
Haley A. Mulder
JPJesse L. Patterson
Jesse L. Patterson
MHMatthew S. Halquist
Matthew S. Halquist
Leon KośmiderLeon Kośmider
Leon Kośmider
JTJoseph B. McGee Turner
Joseph B. McGee Turner
MPMichelle Peace
Michelle Peace
Electronic cigarettes (e-cigarettes) are an alternate nicotine delivery system that generate a condensation aerosol to be inhaled by the user. The size of the droplets formed in the aerosol can vary and contributes to drug deposition and ultimate bioavailability in the lung. The growing popularity of e-cigarette products has caused an increase in internet sources promoting the use of drugs other than nicotine (DOTNs) in e-cigarettes. The purpose of this study was to determine the effect of various e-cigarette and e-liquid modifications, such as coil resistance, battery voltage, and glycol and drug formulation, on the aerosol particle size. E-liquids containing 12 mg/mL nicotine prepared in glycol compositions of 100% propylene glycol (PG), 100% vegetable glycerin (VG), or 50:50 PG:VG were aerosolized at three voltages and three coil resistances. Methamphetamine and methadone e-liquids were prepared at 60 mg/mL in 50:50 PG:VG and all e-liquids were aerosolized onto a 10 stage Micro-Orifice Uniform Deposit Impactor. Glycol deposition correlated with drug deposition, and the majority of particles centered between 0.172–0.5 μm in diameter, representing pulmonary deposition. The 100% PG e-liquid produced the largest aerosol particles and the 100% VG and 50:50 PG:VG e-liquids produced ultra-fine particles <0.3 μm. The presence of ultrafine particles indicates that drugs can be aerosolized and reach the pulmonary alveolar regions, highlighting a potential for abuse and risk of overdose with DOTNs aerosolized in an e-cigarette system.

8 December 2005 in The Journal of Physical Chemistry A
Verified
Journal Article
Closed access
JKJohn F. Kauffman
John F. Kauffman
JTJoseph M. Turner
Joseph M. Turner
Igor V. AlabuginIgor V. Alabugin
Igor V. Alabugin
BBBoris Breiner
Boris Breiner
SKSerguei V. Kovalenko
Serguei V. Kovalenko
STSergei Tretiak
Sergei Tretiak

1 November 2007 in American Journal of Veterinary Research
Verified
Journal Article
Closed access
ESElizabeth K. Schooley
Elizabeth K. Schooley
JTJoseph B. McGee Turner
Joseph B. McGee Turner
RJRenee D. JiJi
Renee D. JiJi
CSChristine M. Spinka
Christine M. Spinka
CRCarol R. Reinero
Carol R. Reinero
Objective—To determine whether oral administration of cyproheptadine or cetirizine blocks the action of serotonin and histamine, respectively, and results in diminished eosinophilic airway inflammation in cats with experimentally induced asthma. Animals—9 cats in which asthma was experimentally induced through exposure to Bermuda grass allergen (BGA) during a 3-month period. Procedures—Cats were randomized to receive monotherapy with each of 3 treatments for 1 week: placebo (flour in a gelatin capsule, PO, q 12 h), cyproheptadine (8 mg, PO, q 12 h), or cetirizine (5 mg, PO, q 12 h). A 1-week washout period was allowed to elapse between treatments. Prior to and following each 1-week treatment period, blood and bronchoalveolar lavage fluid (BALF) samples were collected. The percentage of eosinophils in BALF was evaluated to determine treatment efficacy. Serum and BALF BGA-specific immunoglobulin contents and plasma and BALF histamine concentrations were determined via ELISAs. Plasma and BALF serotonin concentrations were measured by use of a fluorometric method. Results—The mean ± SD percentage of eosinophils in BALF did not differ significantly among treatment groups (placebo, 40 ± 22%; cyproheptadine, 27 ± 16%; and cetirizine, 31 ± 20%). Among the treatment groups, BGA-specific immunoglobulin content and histamine and serotonin concentrations were not significantly different. Conclusions and Clinical Relevance—In cats with experimentally induced asthma, cyproheptadine and cetirizine were not effective in decreasing airway eosinophilic inflammation or in altering several other measured immunologic variables. Neither cyproheptadine nor cetirizine can be advocated as monotherapy for cats with allergen-induced asthma.

15 November 2010 in Journal of Animal Physiology and Animal Nutrition
Verified
Journal Article
Closed access
PDF file
RBR. C. Backus
R. C. Backus
NCNick J. Cave
Nick J. Cave
VGV. K. Ganjam
V. K. Ganjam
JTJ. B. M. Turner
J. B. M. Turner
VBV. C. Biourge
V. C. Biourge